Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Emtricitabine; Nucleoside reverse transcriptase inhibitors; Tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms TOTEM
- Sponsors Gilead Sciences
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2010 Results were presented in the Journal of Antimicrobial Chemotherapy.
- 29 Dec 2009 Actual end date changed from Aug 2008 to Mar 2008 as reported by ClinicalTrials.gov.